Evidence map›Paper›PMID 35834027›Full record

ArticleMedical oncology (Northwood, London, England)2022

Comprehensive transcriptomic and co-expression analysis of ABL1 gene and molecularly targeted drugs in hepatocellular carcinoma based on multi-database mining.

Feifei Lan, Xinqia Chen, Zhuolong Xiong, Zitong Cao, Liangzong Lu, Yueyuan Zhong, Xuliang Zhan, Yue Yang, Yingqi Shao, Minhua Li and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Feifei LanMedical Genetics Center, Guangdong Women and Children Hospital, Guangzhou, China.
Xinqia ChenZhu's Team, Guangdong Medical University, Zhanjiang, China.
Zhuolong XiongZhu's Team, Guangdong Medical University, Zhanjiang, China.
Zitong CaoZhu's Team, Guangdong Medical University, Zhanjiang, China.
Liangzong LuZhu's Team, Guangdong Medical University, Zhanjiang, China.
Yueyuan ZhongZhu's Team, Guangdong Medical University, Zhanjiang, China.
Xuliang ZhanZhu's Team, Guangdong Medical University, Zhanjiang, China.
Yue YangZhu's Team, Guangdong Medical University, Zhanjiang, China.
Yingqi ShaoZhu's Team, Guangdong Medical University, Zhanjiang, China.
Minhua LiZhu's Team, Guangdong Medical University, Zhanjiang, China.
Zenglei HanDepartment of Pathology, Qingdao Municipal Hospital, Qingdao, China. hanzenglei@126.com.
Xiao ZhuZhu's Team, Guangdong Medical University, Zhanjiang, China. bioxzhu@yahoo.com.ORCID http://orcid.org/0000-0002-1737-3386
Guangdong Medical College · CNGuangdong Province Women and Children Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. Consequently, it is essential to identify biomarkers for treatment response and the prognosis prediction. We investigated whether ABL1 can function as a biomarker or a drug target for HCC. We assessed the ABL1 expression, genetic alterations and patients' survival from LinkedOmics, GEO, TCGA and Human Protein Atlas. We analyzed PPI, GO and KEGG pathways. GSEA was analyzed for functional comparison. The current drugs targeting ABL1 were statistically analyzed using DRUGSURV and DGIdb database. We found ABL1 is overexpressed in HCC and its higher expression reduces survival probability. Genetic changes of ABL1 are not frequent. We screened out 25 differentially expressed genes correlated with ABL1. The top functions of ABL1 are biological regulation, metabolic process, protein-containing, and protein binding. KEGG pathways showed that ABL1 and correlated with ABL1 significantly genes markedly enriched in the ErbB signaling pathway, and pathways in cancer. We counted the existing drugs targeting ABL1, which indicates that inhibiting ABL1 expression may improve the survival probability of HCC. In conclusion, ABL1 plays a crucial role in the development and progression of this cancerization and is a potential drug target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPrognosisTranscriptomeABL1Functional network analysisHepatocellular carcinomaMulti-database miningTargeted drugs

Identifiers

PMID35834027
OpenAlexW4285389464

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.